Review





Similar Products

pten  (ATCC)
99
ATCC pten
Compound screening <t>in</t> <t>SH-SY5Y</t> <t>PTEN</t> −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
Pten, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pten/product/ATCC
Average 99 stars, based on 1 article reviews
pten - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier
anti pten  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc anti pten
Compound screening <t>in</t> <t>SH-SY5Y</t> <t>PTEN</t> −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
Anti Pten, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti pten/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
anti pten - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
pten 588  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc pten 588
Compound screening <t>in</t> <t>SH-SY5Y</t> <t>PTEN</t> −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
Pten 588, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pten 588/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
pten 588 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
rabbit anti pten  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc rabbit anti pten
Compound screening <t>in</t> <t>SH-SY5Y</t> <t>PTEN</t> −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
Rabbit Anti Pten, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti pten/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
rabbit anti pten - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
anti pten induced putative kinase 1  (Proteintech)
96
Proteintech anti pten induced putative kinase 1
Compound screening <t>in</t> <t>SH-SY5Y</t> <t>PTEN</t> −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
Anti Pten Induced Putative Kinase 1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti pten induced putative kinase 1/product/Proteintech
Average 96 stars, based on 1 article reviews
anti pten induced putative kinase 1 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
pten cap8 cells  (ATCC)
94
ATCC pten cap8 cells
Compound screening <t>in</t> <t>SH-SY5Y</t> <t>PTEN</t> −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
Pten Cap8 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pten cap8 cells/product/ATCC
Average 94 stars, based on 1 article reviews
pten cap8 cells - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
mcherry fkbp pten  (Addgene inc)
92
Addgene inc mcherry fkbp pten
Compound screening <t>in</t> <t>SH-SY5Y</t> <t>PTEN</t> −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
Mcherry Fkbp Pten, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mcherry fkbp pten/product/Addgene inc
Average 92 stars, based on 1 article reviews
mcherry fkbp pten - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier
gene exp pten hs02621230 s1  (Thermo Fisher)
99
Thermo Fisher gene exp pten hs02621230 s1
Compound screening <t>in</t> <t>SH-SY5Y</t> <t>PTEN</t> −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
Gene Exp Pten Hs02621230 S1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp pten hs02621230 s1/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
gene exp pten hs02621230 s1 - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier
pten cell signaling technology  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc pten cell signaling technology
Compound screening <t>in</t> <t>SH-SY5Y</t> <t>PTEN</t> −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.
Pten Cell Signaling Technology, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pten cell signaling technology/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
pten cell signaling technology - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

Image Search Results


Compound screening in SH-SY5Y PTEN −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.

Journal: iScience

Article Title: Repurposing drugs for treating the neurobehavioral manifestations of PTEN hamartoma tumor syndrome

doi: 10.1016/j.isci.2026.115428

Figure Lengend Snippet: Compound screening in SH-SY5Y PTEN −/− cells (A) Schematic of the PI3K/Akt/mTOR signaling cascade. PTEN counterbalances PI3K activity and loss of PTEN function leads to increased phosphorylation of AKT and downstream activity of mTOR. (B) Using a CRIPSR-based approach, we generated a PTEN −/− SH-SY5Y cell line. Compared to the control SH-SY5Y cells, the newly generated line shows loss of PTEN and concomitant increase of pAKT (Ser473). Loading control, GAPDH. (C–E) Highlighted are three example experiments, using different compounds. The different readouts are labeled in dark (pAKT (Ser473)) and light blue (pS6 (Ser240/244)). (C) Buparlisib similarly reduced both targets with low micromolar IC50. (D) Sapanisertib is effective at even lower concentrations. (E) SCH772984 only modestly decreases pS6 at high concentrations; however, increases pAKT levels. In all three graphs, LDH curves (orange and red) indicate the general viability. None of the displayed compounds shows sign of toxicity, even though LDH levels rise ∼15% in (C). n = 6 for each compound (2 independent experiments with 3 replicates each). Shown are mean and SEM.

Article Snippet: Knockout of PTEN in the SH-SY5Y line (ATCC, CRL-2266) was generated using CRISPR technology.

Techniques: Activity Assay, Phospho-proteomics, Generated, Control, Labeling